ANNX
Annexon, Inc.
$4.71
+0.21%
$771.7M
No data for this timeframe.
Vol
Market Cap$771.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders50 funds
Inst. Value$437.9M
Inst. Activity21 buys / 6 sells
Insider Activity4B / 10S
Insider Net $$3.1M
Reddit Sentiment67° Warm
SEC Reports8
Press Releases1
Recent Activity
Jun 12, 2026
SEC
Goldman Sachs initiates ANNX at Neutral — PT $7 (48% upside)
ANALYST-UPGRADE — Impact 2/10
Jun 10, 2026
short_volume
Short Volume: ANNX — 55.1% short (0.6M / 1.1M)
Short: 589,309 | Exempt: 8,373 | TRF Vol: 1,070,159 | Short Ratio: 55.1% | Off-exchange volume (dark
May 28, 2026
Insider
Satter Muneer A bought 613,497 shares
Director @ $5.41 ($3.3M)
May 11, 2026
Insider
Carson William H. bought 8,000 shares
Director @ $5.78 ($46.2K)
Apr 16, 2026
SEC
Clear Street initiates coverage on ANNX with a Buy rating and $17 price target, implying 193% upside from the current $5
ANALYST-UPGRADE — Impact 8/10
Apr 16, 2026
SEC
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% upside from the current
ANALYST-UPGRADE — Impact 7/10
Apr 10, 2026
Insider
Carson William H. bought 8,000 shares
Director @ $6.20 ($49.6K)
Inst.
STATE STREET CORP — ADD
6,919,255 shares ($38.3M)
Price Targets
$13.13
+178.7% upside
Strong Buy
Current $4.71
Low $7.00
Median $11.50
High $27.00
8 analysts
$7.00
$27.00
Analyst Ratings
4Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Goldman Sachs | INITIATE | Neutral |
| Mar 20, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Dec 23, 2025 | Chardan Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +20.6% | $-0.27 — $-0.22 | 29% YoY | 6 |
| Next Q | $-0.25 ▲ +11.1% | $-0.30 — $-0.21 | 32% YoY | 6 |
| Current FY | $-0.98 ▲ +15.5% | $-1.14 — $-0.86 | 27% YoY | 6 |
| Next FY | $-0.92 ▲ +3.5% | $-1.28 — $-0.64 | 6% YoY | 6 |
Latest Reports
MIXED
ANALYST-UPGRADE
2/10
Goldman Sachs initiates ANNX at Neutral — PT $7 (48% upside)
Jun 12, 2026
BULLISH
ANALYST-UPGRADE
7/10
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% upside from the current
Apr 16, 2026
NEUTRAL
Press
4/10
Annexon Biosciences reported fourth quarter and full year 2025 financial results, highlighting a strong cash position of
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $60.6M | — |
| FMR LLC | $58.9M | TRIM |
| STATE STREET CORP | $38.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.0M | — |
| ADAGE CAPITAL PARTNERS GP, | $23.8M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Satter Muneer | BUY | $3.3M |
| May 11, 2026 | Carson William | BUY | $46.2K |
| Apr 10, 2026 | Carson William | BUY | $49.6K |
| Mar 10, 2026 | Carson William | BUY | $45.4K |
| Mar 2, 2026 | ARTIS DEAN | SELL | $32.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $437.9M total value (79,054,211 shares) as of 2026-Q1. Top holders: BlackRock,, FMR, STATE. Net buying activity: 21 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10,938,509 | $60.6M | 13.8% | — |
| 2 | FMR LLC | 10,635,648 | $58.9M | 13.5% | TRIM -29.4% |
| 3 | STATE STREET CORP | 6,919,255 | $38.3M | 8.8% | ADD +48.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5,956,589 | $33.0M | 7.5% | — |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,300,000 | $23.8M | 5.4% | DOUBLED +266.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 4,259,995 | $23.6M | 5.4% | DOUBLED +165.3% |
| 7 | Nuveen, LLC | 4,246,330 | $23.5M | 5.4% | ADD +45.7% |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | 3,886,909 | $21.5M | 4.9% | DOUBLED +154.3% |
| 9 | AMERIPRISE FINANCIAL INC | 3,449,121 | $19.1M | 4.4% | ADD +98.4% |
| 10 | MORGAN STANLEY | 2,735,970 | $15.2M | 3.5% | DOUBLED +263.9% |
| 11 | Woodline Partners LP | 2,337,137 | $12.9M | 3.0% | TRIM -41.6% |
| 12 | GOLDMAN SACHS GROUP INC | 2,152,880 | $11.9M | 2.7% | — |
| 13 | Point72 Asset Management, L.P. | 1,871,795 | $10.4M | 2.4% | DOUBLED +404.3% |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,483,090 | $8.2M | 1.9% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,102,445 | $6.1M | 1.4% | ADD +33.8% |
| 16 | DIMENSIONAL FUND ADVISORS LP | 924,078 | $5.1M | 1.2% | ADD +28.6% |
| 17 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 903,368 | $5.0M | 1.1% | — |
| 18 | VANGUARD FIDUCIARY TRUST CO | 888,552 | $4.9M | 1.1% | — |
| 19 | MARSHALL WACE, LLP | 861,475 | $4.8M | 1.1% | ADD +65.4% |
| 20 | Invesco Ltd. | 763,005 | $4.2M | 1.0% | DOUBLED +381.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 4,652,185 | 6,919,255 | +48.7% | $38.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,605,581 | 4,259,995 | +165.3% | $23.6M | 2026-Q1 |
| Nuveen, LLC | ADD | 2,915,324 | 4,246,330 | +45.7% | $23.5M | 2026-Q1 |
| Woodline Partners LP | TRIM | 4,000,074 | 2,337,137 | -41.6% | $12.9M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 371,190 | 1,871,795 | +404.3% | $10.4M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 718,680 | 924,078 | +28.6% | $5.1M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 520,998 | 861,475 | +65.4% | $4.8M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 802,600 | 544,300 | -32.2% | $3.0M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 398,077 | 521,379 | +31.0% | $2.9M | 2026-Q1 |
| MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | TRIM | 642,038 | 416,698 | -35.1% | $2.3M | 2026-Q1 |
| Rafferty Asset Management, LLC | ADD | 141,644 | 203,269 | +43.5% | $1.1M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 58,259 | 203,236 | +248.8% | $1.1M | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 126,463 | 159,670 | +26.3% | $884.6K | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 14,757 | 115,527 | +682.9% | $640.0K | 2026-Q1 |
| DnB Asset Management AS | TRIM | 118,324 | 88,617 | -25.1% | $490.9K | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 9,307 | 80,046 | +760.1% | $443.5K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | DOUBLED | 31,585 | 79,173 | +150.7% | $438.6K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 54,763 | 76,257 | +39.2% | $414.1K | 2026-Q1 |
| MetLife Investment Management, LLC | ADD | 39,059 | 72,444 | +85.5% | $401.3K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 123,753 | 58,433 | -52.8% | $323.7K | 2026-Q1 |
| Mariner, LLC | ADD | 31,335 | 53,242 | +69.9% | $294.8K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 17,600 | 40,800 | +131.8% | $226.0K | 2026-Q1 |
| CWM, LLC | ADD | 30,297 | 39,652 | +30.9% | $219.7K | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 46,848 | 22,760 | -51.4% | $126.1K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 2,613 | 7,413 | +183.7% | $41.1K | 2026-Q1 |
8 unique insiders with 25 transactions. Net insider value: $3.1M ($3.5M bought, $313.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Satter Muneer A | Director | BUY | 613,497 | $5.41 | $3.3M |
| May 11, 2026 | Carson William H. | Director | BUY | 8,000 | $5.78 | $46.2K |
| Apr 10, 2026 | Carson William H. | Director | BUY | 8,000 | $6.20 | $49.6K |
| Mar 10, 2026 | Carson William H. | Director | BUY | 8,000 | $5.67 | $45.4K |
| Mar 2, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | SELL | 5,894 | $5.43 | $32.0K |
| Mar 2, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | SELL | 5,820 | $5.43 | $31.6K |
| Mar 2, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | SELL | 5,565 | $5.42 | $30.2K |
| Mar 2, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | SELL | 4,339 | $5.42 | $23.5K |
| Mar 2, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | SELL | 5,566 | $5.42 | $30.2K |
| Feb 19, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | AWARD | 62,500 | — | — |
| Feb 19, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | AWARD | 250,000 | — | — |
| Feb 19, 2026 | Love Douglas | PRESIDENT AND CEO | AWARD | 1,250,000 | — | — |
| Feb 19, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | AWARD | 56,250 | — | — |
| Feb 19, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | AWARD | 225,000 | — | — |
| Feb 19, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | AWARD | 62,500 | — | — |
| Feb 19, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | AWARD | 250,000 | — | — |
| Feb 19, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | AWARD | 62,500 | — | — |
| Feb 19, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | AWARD | 250,000 | — | — |
| Feb 19, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | AWARD | 62,500 | — | — |
| Feb 19, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | AWARD | 250,000 | — | — |
| Feb 18, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | SELL | 7,851 | $5.11 | $40.1K |
| Feb 18, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | SELL | 5,290 | $5.10 | $27.0K |
| Feb 18, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | SELL | 7,857 | $5.11 | $40.1K |
| Feb 18, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | SELL | 6,225 | $5.10 | $31.7K |
| Feb 18, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | SELL | 5,290 | $5.10 | $27.0K |
8 SEC filing reports analyzed. Sentiment: 5 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 4.8/10.
MIXED
ANALYST-UPGRADE
2/10
Goldman Sachs initiates ANNX at Neutral — PT $7 (48% upside)
Jun 12, 2026
BULLISH
ANALYST-UPGRADE
7/10
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% ups
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Clear Street initiates coverage on ANNX with a Buy rating and $17 price target, implying 193% upside
Apr 16, 2026
BEARISH
ANALYST-UPGRADE
4/10
Goldman Sachs initiates ANNX at Neutral — PT $7 (+23%) vs. consensus $13.71
May 12, 2026
BULLISH
ANALYST-UPGRADE
3/10
Chardan Capital initiates ANNX at Buy — PT $16 (+198%) as cluster of bullish coverage builds
May 16, 2026
BULLISH
INST-CLUSTER
5/10
A bullish institutional cluster formed in ANNX during Q3 2025, with 5 buyers accumulating $9.8M in n
Jun 11, 2026
BULLISH
PRESS-RELEASE
6/10
Annexon reported Q1 2026 EPS of -$0.23, beating consensus of -$0.30 by 23%, with net loss narrowing
May 7, 2026
NEUTRAL
CLUSTER
3/10
Five executive officers at Annexon, Inc. (ANNX) sold shares in a coordinated open-market transaction
Mar 4, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 4 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.13 mean target
+178.7% upside
Strong Buy (1.40)
$7.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $4.71 |
| Target Low | $7.00 |
| Target Mean | $13.13 |
| Target Median | $11.50 |
| Target High | $27.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.27 | $-0.22 | 29.5% | +20.6% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.25 | $-0.30 | $-0.21 | 31.9% | +11.1% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.98 | $-1.14 | $-0.86 | 26.7% | +15.5% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-0.92 | $-1.28 | $-0.64 | 6.0% | +3.5% | 3↑ 1↓ | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.240 | |
| 7d ago | $-0.237 | -0.002 |
| 30d ago | $-0.302 | +0.062 |
| 60d ago | $-0.337 | +0.097 |
| 90d ago | $-0.337 | +0.097 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Goldman Sachs | INITIATE | — | Neutral |
| Mar 20, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | Chardan Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 10, 2026
short_volume
Short Volume: ANNX — 55.1% short (0.6M / 1.1M)
Short: 589,309 | Exempt: 8,373 | TRF Vol: 1,070,159 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: ANNX — 66.9% short (0.4M / 0.7M)
Short: 442,181 | Exempt: 0 | TRF Vol: 661,225 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ANNX — 57.4% short (0.5M / 0.8M)
Short: 475,414 | Exempt: 52 | TRF Vol: 827,886 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ANNX — 56.8% short (0.4M / 0.7M)
Short: 411,892 | Exempt: 0 | TRF Vol: 725,184 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: ANNX — 94.0% short (3.3M / 3.5M)
Short: 3,326,317 | Exempt: 0 | TRF Vol: 3,539,125 | Short Ratio: 94.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
other
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next g
May 18, 2026
earnings_calendar
ANNX Q1 2026 Earnings Scheduled — 2026-05-18
May 18, 2026
short_volume
Short Volume: ANNX — 77.6% short (1.0M / 1.3M)
Short: 1,012,793 | Exempt: 9 | TRF Vol: 1,304,950 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ANNX — 73.6% short (0.4M / 0.5M)
Short: 395,249 | Exempt: 15 | TRF Vol: 537,142 | Short Ratio: 73.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: ANNX — 59.0% short (0.3M / 0.6M)
Short: 343,018 | Exempt: 0 | TRF Vol: 581,057 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
ANNX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
<p align="center"><em>Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Re
May 7, 2026
short_volume
Short Volume: ANNX — 56.2% short (0.4M / 0.7M)
Short: 408,824 | Exempt: 4,000 | TRF Vol: 726,869 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 6, 2026
other
Annexon to Present at the Bank of America Securities Health Care Conference 2026
<p>BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platfo
Apr 30, 2026
short_volume
Short Volume: ANNX — 59.2% short (0.4M / 0.6M)
Short: 364,081 | Exempt: 0 | TRF Vol: 614,744 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)